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Exosomes are secreted nanovesicles that are able to transfer their cargo (such as miRNAs) between cells. To
determine to what extent exosomes and exosomal miRNAs are involved in the pathogenesis, progression
and diagnosis of viral infections. The scientific literature (PubMed and Google Scholar) was searched from
1970 to 2019. The complex biogenesis of exosomes and miRNAs was reviewed. Exosomes contain both
viral and host miRNAs that can be used as diagnostic biomarkers for viral diseases. Viral proteins can alter
miRNAs, and conversely miRNAs can alter the host response to viral infections in a positive or negative
manner. It is expected that exosomal miRNAs will be increasingly used for diagnosis, monitoring and even
treatment of viral infections.
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Exosomes are double-membrane vesicles of about 30–150 nm in diameter, with a composition of lipids and proteins
and are enriched with lipid raft-associated molecules. In addition to lipids and proteins, exosomes also contain
nucleic acid molecules, such as DNA, mRNA, viral genomic nucleic acids and miRNAs [1,2]. These exosomal RNAs
can be taken up by neighboring or distant cells, and subsequently modulate behavior of the recipient cells [3]. The
discovery of the biological function of exosomes, where by genetic material can be exchanged between cells has
attracted increasing attention. miRNAs are a class of small noncoding RNAs that play multiple regulatory roles in
a range of cellular processes, such as apoptosis, immune function, tumorigenesis, and they also can both suppress
and contribute to virus replication [4–6]. Several virus families have been demonstrated to encode miRNAs in their
genome, and these can carry out important activities including contributing to evasion of the host immune response,
regulation of viral gene expression, promotion of survival of infected cells, and a possible role in the maintenance
of latent and persistent infection [7,8]. MiRNAs are selectively packaged, released and transferred between cells
encapsulated in exosomes. miRNAs are actively released by exosomes, which protect them from degradation by
RNAses [9]. Viruses use several mechanisms to evade from and suppress the host immune system in order to ensure
their replication and persistence. However, the immune system utilizes a counteracting mechanism for removal of
pathogens [10,11]. Viruses have evolved to insert their viral components into exosomes that exert several downstream
effects by a variety of mechanisms [11]. There have been numerous studies that have demonstrated functional transfer
of exosomal miRNAs between cells both in vitro and in vivo. The functional transfer of exosomes into recipient
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cells leads to the facilitation of virus replication through inhibiting immune responses. It has been found that some
viruses are able to alter the packaging of the miRNAs into the exosomes, suggesting that these alterations could
be beneficial for viral infections [11–13]. Exosomal miRNAs have been found to be present in synovial fluid, breast
milk, urine, blood and saliva. Their amount and compositions differ between healthy and virally infected cells.
Therefore, exosomal miRNAs may play an important role as noninvasive markers for monitoring and diagnosis of
viral diseases. In this review, we discuss the alteration of packaging and dysregulation of miRNAs in the exosomes
derived from virus-infected cells, and outline the implications of these changes for viral infections.
Biogenesis of exosomes
Exosomes were discovered in the early 1980s by Stahl and Johnstone, during their studies on loss of transferrin
during reticulocyte maturation [14]. These authors described exosomes to be complex extracellular vesicles (EVs)
that were secreted by direct budding from the plasma membrane of cells, and could be isolated from human
body fluids and also from cultured cells [15]. Several studies have demonstrated that these small vesicles initially
formed via inward budding inside intracellular endosomes, go on to lead to the formation of multivesicular bodies
(MVBs) [15]. MVBs are late endosomes, which contain intraluminal vesicles (ILVs) and have sizes ranging between
30 and 100 nm in diameter [14,16]. MVBs can either be degraded, or else can fuse with the plasma membrane,
thus releasing ILVs into the extracellular environment. The ILVs released from the MVBs are called exosomes [17].
The biogenesis of exosomes is mediated via the endosomal sorting complex transport (ESCRT) machinery [18].
ESCRT machinery contains four different protein complexes: ESCRT-0, -I, -II, -III and also related AAA ATPase
Vps4 complexes [19]. The most complete study of ESCRTs in exosomes biosynthesis, used an RNAi approach
that targeted 23 ESCRT and ESCRT-related proteins in immortal human cells (HeLa cells) [20]. The exosomes
that are released can be purified by attachment to anti-CD63 beads, and identified by means of anti-CD81 and
anti-HLA-DR (MHC II) fluorescent antibodies using flow cytometry. Using shRNA transfection, seven ESCRT
proteins were recognized in exosomes. Knockdown of the TSG101, ESCRT-0 protein Hrs and the ESCRT-I
protein STAM1 inhibited the release of exosomes. Knockdown of ESCRT-III, and the related proteins VPS4B,
CHMP4C, ALIX and VTA1 enhanced the release of exosomes. In studies of four proteins detected in exosomes by
ultracentrifugation, it was found that reduction of Hrs, TSG101 and STAM1 diminished exosome release, while
VPS4B reduction enhanced exosome release [20–22].
Knockdown of ALIX appeared to alter the protein composition of exosomes, rather than to affect their release.
This could show that ALIX has an effect on cargo loading and/or the subtypes of MVBs, which have been designated
for release. Researchers found that ALIX knockdown in dendritic cells (DCs) diminished exosome release in about
half of the donors.
Moreover, in three different studies, the ESCRT-0 protein Hrs was found to be involved in release of exo-
somes [22,23]. DCs with knockdown of Hrs were found to release fewer exosomes, measured as the exosomal levels
of ubiquitinated proteins, TSG101 and VPS4B. In another study [21], reduction of Hrs in HEK293 cells was found
to diminish exosomal Evi and Wnt3A [22]. In agreement with this result, Camilleri and colleagues used nanopar-
ticle tracking analysis to show that reduction of Hrs-diminished exosome release from head and neck squamous
carcinoma cells [23].
Studies have indicated that membrane proteins containing heparan sulfate chains called syndecans, which are
found within exosomes are regulated through their attachment to the syntenin–ALIX complex. Syntenin is a
polyvalent soluble protein that can bind both ALIX and syndecans, thus creating a connection between syndecans
and the ESCRT machinery [24]. The interplay between syntenin and ALIX also affects the composition of ILVs [24].
The same group also found that heparanases can trim the heparan sulfate side chains of syndecans, thereby assisting
the formation of syndecan clusters, which could induce their attachment to syntenin [25]. Importantly, heparanase
also induced the inclusion of CD63 [25]. The syndecan–syntenin–ALIX complex has been estimated to account for
about 50% of the released vesicles in MCF-7 cells [26]. Studies have suggested that MVB biosynthesis could occur
even when ESCRTs were absent. With the knockdown the subunits of each of the four ESCRT complexes, ILVs were
still created in MVBs, showing the existence of ESCRT-unrelated pathways [27]. Tetraspanins are transmembrane
proteins, which are abundant in exosomes, and may also be involved in exosome release [28]. The release of exosomes
containing β-catenin from HEK293 cells, was shown to be related to the expression of the tetraspanins, CD9 and
CD82.
It was shown that bone marrow DCs (BMDCs) isolated from CD9 knockout mice released less exosome-related
flotillin-1. Another tetraspanin, involved in exosome biosynthesis is Tspan8 [29]. The expressing of Tspan8 in rat
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adenocarcinoma cells affected the total number of released exosomes, with little effect on the mRNA and protein
contents of the exosomes. The tetraspanin, CD63 has also been shown to be involved in exosome biosynthesis [30].
Researchers have shown that cells, which express Epstein–Barr virus (EBV)-encoded latent membrane protein 1
(LMP1) released more exosomes in comparison with cells without LMP1, and that this LMP-1 effect also involved
CD63 [31]. The ‘small integral membrane protein of the lysosome or late endosome’ (SIMPLE) as well as the
‘lipopolysaccharide-induced TNF factor’ LITAF, are proteins that have been suggested to be important in exosome
formation. After transfecting COS cells with SIMPLE (and mutated SIMPLE) an increased release of exosomes
was detected [32]. As well as proteins, lipids have critical roles in vesicular transport [33]. Two kinds of lipid-related
processes contribute to vesicular transport, namely, membrane fission and destruction, and membrane fusion [34].
Membrane deformation is governed by the type of membrane lipids, including the degree of saturation of the acyl
chains, the size and length of the head group.
Many studies have indicated the participation of lipids in the exosome composition through lipid-regulating
enzymes. Blocking nSMase2, the enzyme, which produces ceramide from sphingomyelin, decreases the release of
exosomes containing proteolipid protein from Oli-neu cells [35]. A similar study showed that blocking nSMase2
decreased the secretion of exosomal EGFP-CD63 from EGFP-CD63-transfected PC-3 cells. The mechanisms for
these effects are obscure, but it may be that ceramide microdomains coalescence in larger domains, which then
enhance membrane budding [35]. Researchers have proposed that role of ceramide in exosome secretion is unlikely,
due to their high-speed growth [36,37], but this does not apply to all the cell lines in which it was evaluated [38].
For instance, in PC-3 cells, exosomes are secreted via nSMase2, and blocking de novo ceramide production had
no effect [38]. Phospholipase D2 (PLD2), which generates phosphatidic acid (PA) from phospholipids, is another
lipid-regulating enzyme whose role has been assessed in exosome production. The action of this enzyme was related
to the secretion of exosomes in RBL-2H3 cells [39]. PLD2 was proposed to function as a modulator of the small
GTPase, ARF6 that has been recognized as a modulator of exosome biosynthesis and governs the composition of
ILVs [40]. The direct involvement of PLD2-produced PA in exosome biosynthesis was not proposed. In another
study, diacylglycerol kinase α (DGKα; an enzyme that adds a phosphate group to diacyl glycerol producing PA) was
implicated in the secretion of exosomes from T lymphocytes [41]. However, DGKα was found to have a negative
effect on the construction of mature MVBs [29]. Furthermore, DGKα was found to interact with protein kinase
D1/2 to promote MVB maturation and exosome release [42]. As mentioned above, exosome biosynthesis can be
divided into ESCRT-related and ESCRT-unrelated pathways [43], but these pathways might not be completely
separate [44]. One pathway might act as an enhancer of the other pathway. In addition, the cell types and/or state
of cellular homeostasis might be critical factors in exosome release.
MiRNA biogenesis
Most miRNA genes are found within the introns of protein encoding, as well as noncoding genes [45]. The majority
of miRNAs are transcribed by RNA polymerase II, as long primary miRNAs. This process is regulated by the
MEDIATOR complex. Furthermore, cyclin-dependent kinases such as CDKF1 and CDKDs phosphorylate the
C-terminal domain of the largest subunit of RNA polymerase II [46]. Some transcription factors regulate the
transcription of miRNA genes and miRNA-related pathways, for example, NOT2 interacts with RNA polymerase
II, and regulates the transcription of some miRNA genes [46]. Primary miRNA (pri-miRNA) consists of a hairpin
structure composed of a terminal loop and a stem region. Pri-miRNA is 5′-capped, spliced and polyadenylated,
producing one (or more) functional miRNA molecule [47]. The RNase III enzymes, Dicer and Drosha specifically
process these ‘pri-miRNAs’ to generate mature miRNA duplexes containing 19–24 nucleotides (Figure 1) [48].
In the nucleus, ‘microprocessor’, a multiprotein complex, first crops the pri-miRNAs into an approximately 70
nucleotide hairpin-structured precursor called pre-miRNA. Next Drosha and DGCR8/Pasha (which is a dsRNA-
binding domain [dsRBD] protein) that are the two major components of the microprocessor, together with
the cofactors DDX5, p72 (DDX17) and heterogeneous nuclear ribonucleoproteins (hnRNPs) [47] work together
to cleave the double-stranded region of the pre-miRNA to produce a 2-nt 3′ overhang, which is recognized
by XPO5 and promotes translocation of the pre-miRNA from the nucleus to the cytoplasm via a Ran-GTP-
dependent mechanism [49,50]. In the cytoplasm, Dicer (another RNase III enzyme) working with the dsRBD
proteins, TRBP/PACT, further cleaves the pre-miRNA into an approximately 22-nt long miRNA duplex.
One strand of the miRNA duplex, usually an A/G rich strand with a 5′-U initiation site called the guide
strand binds to an Argonaute (AGO) protein within the RNA-induced silencing complex (RISC). The duplex
passenger strand is U/C rich, and usually begins with a 5′-C, and is destined to be degraded. Based on expression
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Figure 1. Biogenesis of exosomes in parent cells and uptake of exosomes by recipient cells. Showing how membrane pathways,
vesicular pathways and mRNA/miRNA pathways are all involved.
profiling, both strands can be equally abundant in some tissues [48]. The miRNA guides the RISC to bind to the
targeted mRNA sequence at the 3′UTR, thus destroying the mRNA, leading to dysregulation of the target gene
expression [47,51].
Furthermore, some alternative Drosha-independent pathways of miRNAs processing have been found, such as
tRNA- and snoRNA-derived miRNAs, and mirtrons. Although one strand of miRNA is loaded into Ago for mRNA
binding leading to gene repression, by means of RNA-binding proteins (RBPs), the other strand is transported
toward the plasma membrane for secretion in microvesicles, or else toward MVBs for secretion in exosomes. The
assessment of the miRNA content of exosomes derived from cardiac fibroblasts, showed the abundance of several
passenger strands of miRNA [52]. The absence of Ago2 from exosomes suggests that exosomal miRNAs are guided
by RBPs, as well as protected against degradation [53].
RBPs play a role in the transportation of the miRNA strands either toward MVBs for loading into exosomes, or
toward the plasma membrane for secretion. After the transportation of endosomes to the trans-Golgi network, they
can be routed to lysosomes for degradation, or else interact with microtubules to bind to the plasma membrane,
leading to release of ILVs as exosomes into the extracellular space. Exosomes are able to interact with recipient cells
via membrane fusion, endocytosis or juxtacrine signaling. By the outward budding of the plasma membrane, the
parent cells also release microvesicles into the extracellular space.
Lipid-induced loading of RNA into exosomes
Spontaneous inward budding of the raft-like areas of the membrane of MVBs creates ILVs, and the exosomes
that are formed are enriched in phosphatidylcholine (PC), saturated fatty acids, glycosphingolipids, sphingomyelin
and cholesterol (Figure 2). Loading of RNAs into exosomes, commences after binding of RNAs to the raft-like
areas [54]. The binding of RNAs to the membranes is mediated through numerous factors, including sphingosine,
lipid structures (especially lipid rafts) and hydrophobic modifications [55,56]. Some specific nucleotide sequences
show increased affinity to the phospholipid bilayers [57–59]. Indeed, by combining such preselected RNA motifs with
high membrane affinity along with an amino acid-binding RNA motif, a passive membrane transporter specific
for the amino acid tryptophan was constructed and characterized [60]. The existence of interactions between the
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Figure 2. RNAs binding to raft-like areas of the cytoplasmic surface of the multivesicular body membrane. There is an interaction
between the cytoplasmic leaflet of the MVB membrane and RNAs that are transported by RBPs. The highest affinity of RNAs to the
raft-like areas occurs at the membrane. The affinity of the RNA molecule to the raft-like areas is governed by hydrophobic areas of RNA,
and RNA sequence-dependent binding motifs. Both glycosphingolipid and lysophospholipid molecules present at the luminal surface, as
well as ceramide molecules in the cytoplasmic membrane surface, mediate the spontaneous inward budding process. After fusion of the
plasma membrane with MVBs, ILVs are generated leading to exosomes.
ILV: Intraluminal vesicle; MVB: Multivesicular body; RBP: RNA-binding protein.
cytoplasmic surface of the MVB membrane and some cellular RNAs has recently been suggested [54]. RNAs are
selected based on their affinity to the raft-like areas in the MVB membrane in order to be incorporated into ILVs,
but the budding process is independent of RNA binding [54].
Raft-like areas in the cytoplasmic surface of the MVB membrane
Because MVBs are an end-product of the endosomal pathway, their formation involves plasma membrane proteins,
such as nSMase2, as well as lipids (including lipids specific for membrane rafts). nSMase2 is palmitoylated on several
cysteine residues within the catalytic site. Sphingomyelin is broken down into ceramide and phosphocholine by
nSMase2 at the inner plasma membrane surface [61]. Topologically, the external surface of the MVB membrane and
the inner surface of the plasma membrane are equivalent. Therefore, ceramide molecules are produced at the MVB
cytoplasmic membrane surface. nSMase2 directly and specifically interacts with PA and phosphatidylserine, and
the nSMase2 enzymatic activity depends on these anionic phospholipids [62], which are enriched in exosomes and
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raft-like areas [63,64]. Ceramide can be converted to S1P and sphingosine via sphingosine kinase and ceramidase [65].
The activation of S1P receptors on MVBs induces their maturation and transports tetraspanins into ILVs [65].
Ceramide is able to self-associate via hydrogen bonding, which provides the driving force for the coalescence
of microscopic rafts into a larger macrodomain [66]. This macrodomain serves as a platform for the process of
ILV budding [67]. The clustering of raft domains and the heterogeneity provided by ceramide, generate active
platform regions within cell membranes [68]. In a study with liposomal membrane consisting of sphingomyelin and
PC, sphingomyelinase causes domain clustering and the formation of membrane microdomains, which leads to
subsequent small vesicles being shed from the membrane into the interior of large liposomes [69].
Lipid-mediated inward budding of the raft-like area of the MVB membrane
Purified exosomes are enriched in ceramide, and when nSMase is inhibited, exosomes release is decreased [70]. In
fact, ceramide stimulates exosome secretion in mammalian cells, and a number of exosomal miRNAs are released
via a secretory process, which is independent of the ESCRT system, and rather depends on ceramide activity [71].
To sort the cargo toward MVBs, an ESCRT independent pathway, working via raft-based microdomains, may
laterally segregate the cargoes within the endosomal membrane [70].
It is likely that the enrichment of exosomes in lyso-phosphatidylethanolamine (lyso-PE) and lyso-PC is important
for the budding process [63,72]. sPLA2-V plays a role in the recycling of endosomes and in the Golgi network [73].
sPLA2-V generates lyso-PE and lyso-PC inside the lumenal surface of MVB membranes. Dipalmitoyl PC is a
major lipid raft component [74]. It can serve as a phospholipase A2 substrate and plays a stabilizing role in raft-like
generation within the MVB membrane. Nonetheless, because of its cylindrical shape, it has not been implicated in
the budding process.
The enrichment of exosomal membranes in glycosphingolipids has been documented. Due to the localization of
glycosphingolipids at the external plasma membrane leaflet, they take up an inward orientation at the endosomal
membrane, leading to their localization at the external surface of ILVs. Specific structures of oligosaccharides as well
as the large hydrophilic head groups of glycosphingolipids, work together to stabilize lipid domains and subdomains
into a positive curvature [75]. Due to their membrane orientation (toward the MVB lumen), glycosphingolipids are
probably not implicated in the interaction of the MVB membrane and RNAs at the cytoplasmic side.
The cone-shaped structure of the ceramide in the raft-like areas of the cytoplasmic membrane surface, as well
as the inverted cone-shaped structures of glycosphingolipids and lysophospholipids in the lumenal membrane
surface induce a pronounced membrane curvature (Figure 2). This results in the process of budding from the MVB
membrane, thus generating ILVs within MVBs. The topology of the budding area correlates with the topology of
the plasma membrane. Due to sPLA2-V at the lumenal side, and nSMase 2 at the cytoplasmic side of the MVB
membrane a larger curvature of the budding area can be attained. Because of the larger surface area of budding
vesicles compared with the border region surface (Figure 2), the driving force for the budding process primarily
comes from the raft-like areas. The opposite curvature of the border region requires cone-shaped lipids at the
cytoplasmic leaflet of the border region. These cone-shaped lipids could move to the border region from the area
of the MVB membrane outside the raft-like region, where lysophospholipids could be created from phospholipids
by the action of cytosolic phospholipases [73].
In the MVB membrane, specific proteins are also able to locate in the raft-like areas [76]. These lipid rafts have
been proposed to be the weak points on the membrane leaflet, which are more disposed to outward budding or
bending [76].
RNA binding to the raft-like areas of the MVB membrane
In contrast to the proteins that are sorted into MVBs by ESCRT in an ubiquitin-dependent manner [77], the
sorting of RNAs is ceramide-dependent and ESCRT-independent in mammalian cells [74]. Additionally, the sorting
of miRNAs into exosomes is probably a passive process designed to dispose of excessive amounts of miRNAs
that are not required for their cellular targets [75]. Since the raft-like areas involve ceramide, it has been suggested
that specific RNA sorting is dependent on the differential affinity of certain RNA motifs to bind to the raft-like
area of the cytoplasmic leaflet of the MVB membrane [78]. This affinity to the raft-like area has been previously
demonstrated [79]. RNAs with a particular sequence and secondary structure may bind to the ordered-liquid domains
in PC-cholesterol-sphingomyelin vesicles resembling the ordered-liquid domains in exosomal membranes [79,80].
Randomly arranged sequences of RNA possess 20-fold lower affinities to the raft regions. Moreover, to increase
the affinity to phospholipid bilayers, particular nucleotide sequences are needed, which are not found in random
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sequences of RNA. Likewise, mRNA fragments enriched in the 3′UTRs that involve sequence elements that
determine the subcellular localization of mRNAs, are transported by exosomes released by human cells [55,81].
The presence of sphingosine increases the affinity of tRNA to membrane rafts [56]. In the MVB membrane,
ceramide is converted to sphingosine via ceramidase. Consequently, in addition to its production in the raft-like
areas, sphingosine may promote RNA affinity to the MVB membrane [82].
Specific exosome-sorting motifs in RNA have been recently proposed for both mRNA and miRNA
(this has been called the EXOmotif ) [83,84]. Remarkably, ten EXOmotifs (UGCC, GGCG, GGAC,
two UCCG, two UGAC, three GCCG) have been found in the raft-binding sequence of RNA 67–
2 [79]: GGGACGACGAUGACACGAUACUUUGUCGGCCGAACUCGCUGCUCCGAUCCGGCGAGAU
CGCAGGGUGUUGCUAUUCGCGUGCCGUGUGCAUACGCCGAUCACAUGACCA [85].
Another 11 EXOmotifs (GGCC, CCCG, GGCG, GGAC, two UGCC, two UGAC, three GCCG) have been
identified in another raft-binding sequence, RNA 10 [79]: GGGACGACGAUGACACGAUACUUUGUCGGC
CGAACUCGCUGUUUAACUGCCCGGCGAGAUCGCAGGGUGUUGUGCUAUUCGCGUGCCGUG
UGCAUACGCCGAUCACAUGACCA. It was found that, among the all the examined RNA sequences, RNA
10 and RNA 67–2 possessed the most powerful affinity to the raft-like region [79]. According to recent data, RBPs
have an important role in miRNA delivery to the raft-like regions [54]. In fact, the exosomal release of miRNA
is promoted by its sequence-dependent correlation with hnRNPA2B1 (heterogeneous nuclear ribonucleoprotein
A2/B1) [84]. Interestingly, hnRNPA2B1 protein possesses a high affinity to ceramide-rich membrane regions [84]
and can be detected in exosome independently of miRNAs. Ago2 is usually absent from exosomes, which suggests
that, independently of the miRNA production process, preformed miRNAs are released in exosomes [53]. Due
to the presence of miRNAs in a 13-fold excess over the amount of Agos in HeLa cells, there are excess miRNAs
available to bind to the raft-like areas of MVBs [86].
According to recent data, miRNAs that bind to Ago without interacting with target mRNAs are susceptible to
degradation, whereas miRNAs that interact with target mRNAs are protected [48].
Furthermore, the raft-like regions of MVB are able to act as a target for miRNAs. Thus, independently of
Ago, miRNAs binding either to the MVB raft-like regions, or to mRNAs themselves protects the miRNAs against
degradation [54]. The high abundance of several passenger strands of miRNAs found in exosomes, may result from
this protective property of the raft-like regions [52].
Exosomal miRNAs in viral infections
As mentioned above, the critical role miRNAs in most biological processes, such as differentiation, proliferation,
development and tumorigenesis, has described by several studies [87,88]. miRNAs regulate the expression of genes
via binding to the 3′UTR of the target mRNA, which leads to dysregulation of target gene expression [51]. A single
miRNA has the ability to influence several genes within any individual cell, or even affect the gene expression in
adjacent cells and distant cells by the export mechanism. The export of miRNAs is mediated through active transport
via the nuclear exporter XPO5 [89]. Recent studies have shown that miRNA secretion is partially carried out by
exosome-mediated transfer mechanisms [86]. The roles of exosomal miRNAs in the regulation of the intercellular
communications that occur in viral infections have been established (Table 1) [90].
Exosomal miRNAs in infections with DNA viruses
Gibbings et al. reported that exosomal transportation was involved in the modulation of miRNA activity in HeLa
cells [77]. In addition to the host miRNAs, viral miRNAs have also been detected in exosomes derived from
virus-infected cells. For example, some studies have detected BamHI fragment A rightward transcript (BART) viral
miRNAs (ebv-miR-BHRF1-1 and ebv-miR-BART3) in exosomes originating from nasopharyngeal carcinoma cells
infected with EBV [95,101]. It was found that ebv-BART15-3p was able to stimulate apoptosis in cancer cells through
targeting Baculoviral IAP BIRC6 and TAX1BP1 leading to increased chemosensitivity of gastric cancer cells [102,103].
The effect of exosomal ebv-BART15-3p on cancer cells has not yet been studied and requires further investigation.
In vitro studies showed that EBV can induce the expression of viral genes in neighboring noninfected cells by
exosomal transmission of EBV-miRNAs. Pegtel et al. reported that exosomes play a critical role in the transfer of viral
miRNAs from EBV-infected B cells to primary immature monocyte-derived DCs, resulting in repression of target
genes [104]. The coculture model was used in this investigation to show that exosomes could transfer EBV miRNAs
from EBV-infected cells to uninfected cells. The coculture approach indicated the transfer of EBV-miRNAs was
more physiologically relevant compared with the use of purified exosomes alone.
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Table 1. Exosomal miRNAs and viral infection.
Virus miRNA Expression Method in the exosome Sample Ref.
Influenza miR-483-3p Up Microfiltration + ultracentrifugation Bronchoalveolar lavage fluid [91]
HCV miR-192 – ExoQuick-TC Cell culture (Huh-7) [92]
HPV16 miR-222-3p Up Differential centrifugation + filtration Cell culture (KSFM) [93]
EBV miR-155 UP Exospin Cell culture (human foreskin
keratinocytes)
[94]
EBV ebv-miR-BART3 – Differential centrifugation + verified by nanosight
and Western blot
Peripheral blood monocular cells [95]
EBV ebv-miR-BHRF1-1 – Differential centrifugation + verified by nanosight
and Western blot
Peripheral blood monocular cells [95]
HIV hsa-miR-29a Up (strongly) Iodixanol gradient + ultracentrifugation Cell culture (HIV-infected macrophage) [96]
HIV hsa-miR-150 Up (strongly) Iodixanol gradient + ultracentrifugation Cell culture (HIV-infected macrophage) [96]
HIV hsa-miR-875 Up Iodixanol gradient + ultracentrifugation Cell culture (HIV-infected macrophage) [96]
HIV hsa-miR-518f Up Iodixanol gradient + ultracentrifugation Cell culture (HIV-infected macrophage) [96]
HIV hsa-miR-1243 Up Iodixanol gradient + ultracentrifugation Cell culture (HIV-infected macrophage) [96]
HIV hsa-miR-1274a Up Iodixanol gradient + ultracentrifugation Cell culture (HIV-infected macrophage) [96]
HIV hsa-miR-302c Up Iodixanol gradient + ultracentrifugation Cell culture (HIV-infected macrophage) [96]
HIV hsa-miR-872 Up Iodixanol gradient + ultracentrifugation Cell culture (HIV-infected macrophage) [96]
HIV hsa-miR-636 Up Iodixanol gradient + ultracentrifugation Cell culture (HIV-infected macrophage) [96]
HIV hsa-miR-30e Up Iodixanol gradient + ultracentrifugation Cell culture (HIV-infected macrophage) [96]
HIV hsa-miR-548a Up Iodixanol gradient + ultracentrifugation Cell culture (HIV-infected macrophage) [96]
HIV hsa-miR-454 Up Iodixanol gradient + ultracentrifugation Cell culture (HIV-infected macrophage) [96]
HIV hsa-miR-338 Up Iodixanol gradient + ultracentrifugation Cell culture (HIV-infected macrophage) [96]
EV71 miR-146a – Exoquick Serum [97]
HSV-1 miR-H28 – Life Technology Cell culture (HEK293T and HEp-2) [98]
HSV-1 miR-H29 – Life Technology Cell culture (HEK293T and HEp-2) [98]
KSHV miR-92a – Ultracentrifugation + microfiltration + ExoQuick-TC Cell culture (BCBL-1) [99]
KSHV mir-10b-5p – Ultracentrifugation + microfiltration + ExoQuick-TC Cell culture (BCBL-1) [99]
KSHV mir-143-3p – Ultracentrifugation + microfiltration + ExoQuick-TC Cell culture (BCBL-1) [99]
KSHV miR-K12-8-3p – Ultracentrifugation + microfiltration + ExoQuick Cell culture (BCBL-1) [99]
KSHV miR-K12-4-3p – Ultracentrifugation + microfiltration + ExoQuick-TC Cell culture (BCBL-1) [99]
KSHV miR-K12-2-5p – Ultracentrifugation + microfiltration + ExoQuick-TC Cell culture (BCBL-1) [99]
KSHV miR-17-92 cluster Up Filtration + ultracectrifugation + ExoQuick In vitro [100]
KSHV KSHV-miRs – Filtration + ultracectrifugation + ExoQuick In vitro [100]
EBV: Epstein–Barr virus; EV71: Enterovirus 71; HCV: Hepatitis C virus; HPV: Human papillomavirus; KSFM: Keratinocyte-serum-free media; KSHV: Kaposi sarcoma-associated
herpesvirus.
The Kaposi sarcoma-associated herpesvirus (KSHV or HHV8) modifies its microenvironment by transferring
its miRNAs within secreted exosomes, from KSHV-infected lymphatic endothelial cells to adjacent cells. While
neighboring cells remained uninfected, the KSHV miRNAs influence these cells by downregulating the expression
levels of their target genes. These changes lead to a metabolic shift into aerobic glycolysis and to decreased
mitochondrial biogenesis in primary lymphatic endothelial cells. This process reduced the sensitivity of exosome-
recipient cells to KSHV, but increased their potential for angiogenesis and migration [13].
In a recent study, Honegger et al. examined the effect of human papillomavirus (HPV) oncogenes on the miRNA
composition of exosomes. They reported that continuous expression of HPV E6 and E7 oncoproteins was linked
to the downregulation of miR-21-5p, and upregulation of miR-20a-5p, miR-423-3p, miR-92a-3p, miR-378a-3p,
miR-7-5p and let-7d-5p in exosomes released from HeLa cells [12]. Some of these miRNAs may be involved in
cancer-associated growth and progression [105]. For example, let-7d-5p (which is a member of the let-7d family)
has antiapoptotic activity. A recent study reported that the expression of let-7d-5p was significantly increased
during breast cancer progression [106]. miR-423-3p has been found to be involved in cell growth, and promotes
the G1/S cell-cycle transition [107]. These findings suggest that the endogenous expression of HPV E6/E7 in
cancer cells is associated with alteration of the miRNAs within exosomes, partially explaining the antiapoptotic or
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pro-proliferative effects [12]. Recent studies have found that miR-222-3p and miR-320a are expressed in exosomes
originating from primary human foreskin keratinocytes (HFKs). Interestingly, miR-222-3p and miR-320a were
respectively downregulated and upregulated inside HPV16 E6/E7-infected HFKs, while these miRNAs were
upregulated and downregulated in the bexosomes that were released from infected cells [93,108]. These data suggest
that miRNAs can be selectively packaged into exosomes. Harden and Munger examined the effect of exosomal
miRNAs secreted from HFKs on the processes of necrosis, apoptosis and cell survival. They suggested that the
expression of HPV16 E6 and E7 proteins in transfected HFKs inhibited necrosis and apoptosis in adjacent normal
cells through the effect of exosomal miRNAs [108]. In HPV infection, the HPV genome integrates into the host
genome. This integration results in the complete or partial loss of the E1 and E2 genes, which modulate the activity
of the viral oncoproteins E6 and E7. However, no investigations have yet been carried out to compare the expression
profiles of exosomal miRNAs in HPV-integrated cells in comparison with nonintegrated HPV DNA.
BK viral nephropathy (BKVN) is caused by the BK polyoma virus (BKV), and leads to graft failure and
deterioration of transplanted kidneys in recipients receiving immunosuppression [109]. Molecular surveillance
utilizing BK viral load assays in urine samples and plasma has led to the number of proven BKVN biopsies
declining (1–10% rate of infection) [110]. Nevertheless a considerable proportion of infected kidney transplant
recipients suffer from graft injury with a 10–80% rate of graft loss [109]. It has been recently reported that BKV-
encoded miRNAs can be detected in the urine and blood of BKV-infected patients [111].
Kim et al. assessed the expression of BK viral miRNAs in exosomes in the urine during virus replication, and the
possible diagnostic property to identify BKVN in recipients of kidney transplants [112]. Their findings reported that
high concentrations of bkv-miR-B1-3p and bkv-miR-B1-5p were observed in all the BKVN patients. Meanwhile,
plasma and urinary BK viral load assays displayed a false negative in three and one cases, respectively, among 13
affected patients. The receiver-operating characteristic analysis for bkv-miR-B1-5p/miR-16 and bkv-miR-B1-5p
markers showed a good discriminative power for BKVN, with area under the curve values of 0.985 and 0.989,
respectively. Their results suggested that detection of exosomal bkv-miR-B1-5p/miR-16 and bkv-miR-B1-5p in
urine could be biomarkers for BKVN diagnosis [112]. The fact that BKV can also be detected in the urine from
healthy subjects [113–115] suggests that urinary exosomal BKV miRNAs should be compared between normal
individuals and BKNV patients.
Bayer et al. [116] found that infection with varicella zoster virus could be attenuated in cells that had been
pre-exposed to exosome-packaged miRNA clusters from chromosome 19. Delorme-Axford et al. [117] examined the
effect of miRNAs within trophoblast-derived exosomes on antiviral responses, and found that miRNAs attenuated
the replication of vaccinia virus in recipient cells by induction of autophagy.
Marek’s disease (MD) is a complex lymphoproliferative disease of chickens caused by the ‘Marek’s disease
virus’ (MDV), which is characterized by T-cell lymphoma, immunosuppression and general paralysis [118,119].
MD is generally controlled through administration of vaccines, which lead to protection against the formation of
lymphoma, but does not prevent against superinfection by MDV field strains. In spite of the demonstration of
cell-mediated and humoral immune responses elicited by the vaccine, the mechanisms that elicit protection remain
obscure. Neerukonda et al. investigated the contents of serum exosomes to evaluate their potential role as indicators
of systemic immunity and risk of tumor formation [120]. They studied the protein and RNA contents of serum
exosomes from unvaccinated tumor-bearing chickens (TEX) and from CVI988 (Rispens)-vaccinated chickens
(VEX) using mass spectrometry and deep sequencing. In comparison to TEX, higher amounts of tumor-suppressor
miRNAs were found in VEX, based on bioinformatic analysis of miRNAs. On the other hand, oncomiRs (e.g., miRs
106a-363) as well as miRNA MDV clusters were more abundant in TEX in comparison with VEX. mRNAs that
mapped to the unique long flanking repeats of MDV (IRL/TRL) were found in TEX, while mRNAs that mapped
to the whole genome of MDV were found in VEX. These findings suggested that long-term vaccination responses
could involve the systemic transfer of viral mRNAs to antigen presenting cells. Proteomic analysis of the exosomes
found biomarkers that could distinguish TEX from VEX [120].
Exosomal miRNAs in infections with RNA viruses
Exosomes derived from primary alveolar macrophages (human monocytic leukemia THP-1 cells) infected with
HIV-1 contain the viral miRNAs, vmiR-TAR, vmiR99 and vmiR88. Moreover, these miRNAs have also been
detected in exosomes isolated from HIV-1-infected patient sera. vmiR99 and vmiR88 were demonstrated to
stimulate signaling pathways in macrophages resulting in the robust secretion of TNFα by activation of endosomal
TLR8 [121].
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It has been observed that expression of the HIV Nef (negative regulatory factor) in macrophage-like cells could
modulate the exosomal miRNA composition, and affect specific mechanisms for recruitment and maintenance of
specific miRNAs in exosomes or cells. Astrocytes that were exposed to a combination of morphine and HIV Tat
protein, released exosomes with increased levels of miR-29b [122]. After exposure of human neurons to exosomes
enriched with miR-29b, expression of PDGF B was suppressed, and the viability of neurons was correspondingly
reduced [122]. Argonaute 2 (Ago-2) is an essential protein component of the RISC that mediates miRNA-targeted
gene inhibition. It was observed that exosomes derived from human T-cell line (C8166-45 cells) infected with
human T-lymphotropic virus (HTLV)-1 could manipulate translation of mRNA in recipient cells, suggesting that
the HTLV-1 proteins interfere with Ago-2 function [123]. In mice infected with various influenza virus strains, miR-
483-3p was present at an elevated level in exosomes, which were isolated from bronchoalveolar lavage fluid. RNF5
and CD81 are regulators of the RIG-I signaling pathway, and both of them are miR-483-3p targets in MLE-12 cells.
Maemura et al. reported that transfection of miR-483-3p induced expression of proinflammatory cytokine and
type I interferon, in MLE-12 (murine lung epithelial) cells infected with influenza virus infection. Taken together,
these studies showed that bronchoalveolar lavage fluid exosomal miRNAs could mediate the inflammatory and
antiviral responses after influenza infection [91].
miRNAs act as key mediators in the liver disease induced by hepatitis C virus (HCV) [124]. The pattern of
miRNA expression is altered in hepatic stellate cells (HSCs) infected with HCV. The HCV core protein leads
to increased miR-192 levels in hepatocytes, and miR-192 can stimulate transcription of TGF-b1 by targeting
ZEB1 [125]. Kim et al. identified miR-192 in the exosomes released from the hepatocyte cell line (Huh-7) infected
with HCV. Exosomes can stimulate the transdifferentiation of the LX-2 HSCs line, and trigger the transformation
of HSCs into myofibroblasts via the action of TGF-β1 [92].
Exosomes are also significant mediators of the interaction between tumors and their environment. Cancer-
derived exosomes can effectively disrupt the integrity of the vascular endothelial barrier and disrupt tight junctions to
promote tumor cell metastasis [126]. Additionally, exosomes secreted by lung cancer cells can regulate their migration
by IL-10 and TGF-β signaling [127]. Moreover, exosomes released from mesenchymal stem cells could inhibit HCC
cell proliferation. Mast cell-originated exosomes activate T and B lymphocytes to play a proinflammatory role [128].
The tumor-suppressor miR-490 plays a significant role in the invasion, migration and growth of breast, ovarian and
colon cancers [129–131]. Furthermore, miR-490 regulates the metastasis and proliferation of HCC cells via targeting
Endoplasmic Reticulum-Golgi Intermediate Compartment Protein 3 [132]. On average, 70% of liver cancer cells
express a high level of EGFR, and activated EGFR has an important role in migration and angiogenesis [133,134].
EGFR inhibition is a potential therapeutic approach for cancer treatment. Xiong et al. found that the E2 protein
of HCV increased the level of miR-490 in exosomes derived from mast cells, and when transferred to recipient
HCC cells, eventually decreased the activity of the EGFR/AKT/ERK1/2 signaling pathway and inhibited HCC
cell migration [126].
Interferons (IFNs) are cytokines produced by cells as a defensive response against viruses [135]. Some viruses,
which indirectly interfere with TRAF6 and RAK1, two important factors involved in IFN production and TLR
signaling, are able to escape the antiviral effects of IFN. It has been shown that infection with enterovirus 71
(EV71) can upregulate miR-146a that facilitates the pathogenicity of the virus via suppression of STAT1, IRAK1
and TRAF6 [136]. In order to validate the effect of miR-146a, a mouse-adapted version of the virus mEV71 was
established from human EV71. The mice were orally infected with mEV71, and pulmonary edema, mortality, loss
of body weight and paralysis were similar to those symptoms seen in humans. However, some pathological findings
in the EV71-infected mice were not identical to human clinical findings. Of note, heart failure, pulmonary edema
and limb paralysis symptoms that have been observed in humans may be due to the lytic EV71 replication in the
CNS, while the replication of mEV71 may occur in a wider range of organs in mEV71-infected mice. Therefore,
whether EV71-infected animals can be used to discover novel antiviral therapies for clinical trials, as well as to
understand the underlying pathological mechanisms requires further evaluation [136]. Fu et al. showed that exosomes
released from EV71-infected human monocytic leukemia (THP-1) cells and human colon cancer (HT-29) cells
selectively contained high levels of miR-146a. These exosomes could be functionally transferred into recipient cells
and facilitate the replication of the virus by suppressing IFN responses [97]. Moreover, because of the similarity
between exosomes and EV71 virions in terms of their sedimentation velocity and buoyant density [137,138], the
sucrose gradient isolation technique and traditional ultracentrifugation is not guaranteed to isolate pure exosomes
that are free from cellular and viral contamination. Therefore, a CD63 immunomagnetic bead isolation technique
was optimized for purifying EV71-related exosomes, without any carryover of free virus, and used to confirm that
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Figure 3. Exosomal miRNA biogenesis in viral infection. Certain viral proteins such as ECV-E2 and EV71 can change the miRNAs in
exosomes. On the other hand, certain miRNAs can affect host response to viruses and either stimulate or inhibit infection.
the EV71 RNA was indeed intra-exosomal. EV71 infection was recently revealed to be an infection that could
be transmitted through exosomes [139]. Although the viral proteins were detected in the exosomes isolated from
RD cells infected by EV71 [139], they were not found in the exosomes in all the situations that were studied. This
difference may be because the two-step purification approach is superior to ultracentrifugation alone, and can avoid
isolating exosomes contaminated with multiple foreign proteins [140,141].
Bayer et al. [116] found that the infection of cells with rubella, other togaviruses and HIV-1 could be attenuated
if the cells had been pre-exposed to exosome-packaged miRNA clusters from chromosome 19. Delorme-Axford et
al. [117] demonstrated that miRNAs contained within trophoblast-derived exosomes showed antiviral activity, and
attenuated viral replication in recipient cells by the induction of autophagy. They found that human miR-512-3p,
miR-516b-5p and miR-517-3p, which were packaged within primary human trophoblast (PHT)-derived exosomes
conferred viral resistance to recipient cells. They showed that exposure of PHT recipient cells and non-PHT recipient
cells including HeLa, U2OS and human foreskin fibroblasts for 24 h before infection, to miRNAs isolated from
naive PHT cells decreased the replication of several viruses including coxsackievirus B, vesicular stomatitis virus
and HCV [117].
Exosomal miRNAs have been consistently detected in saliva, blood, urine, breast milk and synovial fluid.
The composition and amount of exosomal miRNAs are different between virally infected and noninfected cells.
Therefore, exosomal miRNAs may play a potential role as noninvasive biomarkers for diagnosis and monitoring of
viral diseases.
Taken together, the above-mentioned evidence suggests that exosomal miRNAs originating from virally infected
cells, can alter the expression of target genes in recipient cells and therefore they could be used to control viral
diseases. Figure 3 illustrates the biogenesis of exosomal miRNAs in viral infections.
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The functions of exosomes in viral infections
As previously mentioned, exosomes isolated from virus-infected cells contain many viral components such as
proteins, mRNAs, genomic RNA and miRNAs. Exosomes secreted from HIV-infected cells contain the viral
transactivation response element and lead to elevated HIV replication in the recipient cells by downregulating
apoptosis [142]. Esser et al. reported that MHC class II, CD86 (B7-2) and CD45 molecules were all contained
in exosomes originating from immune cells (H9, CEMX174/T1, CEMX174/T2 and TBLCL-CD4) infected
with HIV-1. These mediators are likely to be involved in silencing the immune response, thus favoring virus
replication [143]. Because exosomes play a significant role in tumor pathogenesis, it is not surprising that many
oncogenic viruses from several DNA virus families, and different RNA viruses such as flaviviruses and retroviruses,
have been shown to interfere with the normal exosomal communication function. Some of the HPV subtypes
(HPV16 and 18) are associated with cervical malignancy. Several studies have reported that exosomes released
from cells infected with oncogenic HPV subtypes were enriched with miRNAs that controlled cell apoptosis and
proliferation. The Tax protein of HTLV-1, which is an important factor for transformation and proliferation of
CD4+ T lymphocytes, was found to be incorporated in exosomes derived from HTLV-infected cells. Overall,
exosomes from virus-infected cells and from cancer cells tend to promote the progression of viral infections or
malignancy by adversely affecting the function of normal recipient host cells.
Conclusion & Future perspective
Viral infections are known to be a very important cause of respiratory tract disease in the outpatient setting, but
much less common in the intensive care unit. It has been shown that viral infections exert their pathological impact
though activation/inhibition of a wide range of cellular and molecular mechanisms.
Exosomes are a new class of mediators involved in intercellular signaling, which have been implicated in several
different diseases and pathological conditions, including viral-infections. Increasing evidence has suggested that
exosomes can target their cargos to recipient cells, and are able to change the behavior of these cells. A variety of
biological molecules (RNA, DNA, proteins and lipids) can be transferred by exosomes. miRNAs are epigenetic
regulators that exert their effects via downregulating gene expression, and also affecting a range of cellular and
molecular pathways. The transfer of these miRNAs into various recipient cells by means of exosomes is associated
with an alteration in different aspects of cellular behavior. The ability of exosomes to transport miRNAs to adjacent
cells or even to distant cells may explain some novel modulatory mechanisms, which are characteristic of viral
infections. Many studies on exosomes secreted from virus-infected cells have suggested that modulation of the
exosomal miRNA composition during viral infection is a regulated process, in which multiple mechanisms for
production or maintenance of specific miRNAs are involved. Therefore, it is likely that manipulation of exosomal
miRNAs by specific viruses contributes to the viral escape from the host immune response, promotes survival of
infected cells, allows spread of infection to noninfected cells and maybe play a role in the maintenance of latent
and persistent viral infections.
It seems that further study of exosomal miRNAs, especially as they are related to viral infections, could open
new horizons in the development of new diagnostic biomarkers and therapeutic approaches for the treatment of
patients who are infected by viruses. In addition, viral miRNAs and host-related miRNAs are also involved in
various types of viral latency. Hence, the characterization of miRNAs (derived from the host cells and also from
the viral genome) contained in exosomes is important to fully understand the viral life cycle. Various reports have
assessed the host and/or viral miRNA expression profiles in viral-associated tumor tissues and in viral-infected cell
lines by real-time quantitative PCR, microarrays and next-generation sequencing assays. Little is understood about
host and viral miRNA expression profiles in exosomes that are derived from viral-infected cells. Hence, more work
is needed to gain a precise understanding of the cellular and molecular pathways, which are either activated or
inhibited by host miRNAs and/or viral miRNAs.
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Executive summary
Biogenesis of exosomes
• Exosomes are secreted by direct budding from the plasma membrane of cells, and can be isolated from cultured
cells and also from human body fluids.
• The biogenesis of exosomes is mediated via the endosomal sorting complex transport machinery.
• Cells expressing Epstein–Barr virus (EBV)-encoded LMP1 released more exosomes in comparison with control cells,
and involved CD63.
MiRNA biogenesis
• The majority of miRNAs are transcribed as long primary miRNAs. This process is regulated by the MEDIATOR
complex.
• One guide strand of miRNA duplex, usually an A/G-rich strand with a 5′-U initiation site binds to Argonaute
protein within the RNA-induced silencing complex.
• The miRNA guides RNA-induced silencing complex to bind to complementary target mRNA, and represses its
translation via binding to the 3′UTR.
• There may also be lipid-induced loading of RNA into exosomes.
• Spontaneous inward budding of the raft-like areas of the multivesicular body membrane creates intraluminal
vesicles, enriched in phosphatidylcholine, saturated fatty acids, glycosphingolipids, sphingomyelin and
cholesterol.
• The binding of RNAs to the membrane is mediated via sphingosine, lipid structures (especially lipid rafts) and
hydrophobic modifications. Some specific nucleotide sequences show increased affinity to phospholipid bilayers.
• RNAs are selected based on their affinity to the raft-like areas in the multivesicular body membrane to be
incorporated into intraluminal vesicles, but the budding process is independent of RNA binding.
Exosomal miRNAs in infections with DNA viruses
• Exosomal transportation is involved in the modulation of miRNA activity in cells.
• Host miRNAs and viral miRNAs have also been detected in exosomes derived from virus-infected cells.
• BamHI fragment A rightward transcript (BART) viral miRNAs (ebv-miR-BHRF1-1 and ebv-miR-BART3) have been
detected in exosomes originating from nasopharyngeal carcinoma cells-infected with EBV.
• EBV can induce the expression of viral genes in neighboring noninfected cells by exosomal transmission of
EBV-miRNAs.
Exosomal miRNAs in infections with RNA viruses
• Exosomes derived from primary alveolar macrophages (human monocytic leukemia THP-1 cells) infected with
HIV-1 carried viral miRNAs, vmiR-TAR, vmiR99 and vmiR88. These miRNAs have also been detected in exosomes
isolated from HIV-1-infected patient sera.
• The expression of the HIV Nef (negative regulatory factor) in macrophage-like cells can modulate exosomal
miRNA composition, and affects the mechanisms for recruitment and maintenance of specific miRNAs in
exosomes or cells.
• Exosomes released from enterovirus 71-infected human monocytic leukemia (THP-1) cells and human colon
cancer (HT-29) cells both contained high levels of miR-146a.
References
Papers of special note have been highlighted as: • of interest; •• of considerable interest
1. Zhang J, Li S, Li L et al. Exosome and exosomal microRNA: trafficking, sorting, and function. Genomics, Proteomics Bioinformatics
13(1), 17–24 (2015).
• Covers the underlying mechanisms of exosome biogenesis and miRNA trafficking.
2. Pelchen-Matthews A, Raposo G, Marsh M. Endosomes, exosomes and Trojan viruses. Trends Microbiol. 12(7), 310–316 (2004).
3. Hu G, Drescher KM, Chen X. Exosomal miRNAs: biological properties and therapeutic potential. Front. Genet. 3, 56 (2012).
• Discusses possible therapeutic roles of exosomal miRNAs.
future science group www.futuremedicine.com 365
Review Nahand, Tehran, Moghoofei et al.
4. Trobaugh DW, Klimstra WB. MicroRNA regulation of RNA virus replication and pathogenesis. Trends Mol. Med. 23(1), 80–93 (2017).
• Discusses the role of miRNAs in viral pathogenesis.
5. Wang L, Li G, Yao ZQ, Moorman JP, Ning S. MicroRNA regulation of viral immunity, latency, and carcinogenesis of selected tumor
viruses and HIV. Rev. Med. Virol. 25(5), 320–341 (2015).
6. Su Z, Yang Z, Xu Y, Chen Y, Yu Q. MicroRNAs in apoptosis, autophagy and necroptosis. Oncotarget 6(11), 8474 (2015).
7. Plaisance-Bonstaff K, Renne R. Viral miRNAs. In: Antiviral RNAi. Springer, 43–66 (2011).
8. Naqvi AR, Shango J, Seal A, Shukla D, Nares S. Viral miRNAs alter host cell miRNA profiles and modulate innate immune responses.
Front. Immunol. 9, 433 (2018).
9. Bhome R, Del Vecchio F, Lee G-H et al. Exosomal microRNAs (exomiRs): small molecules with a big role in cancer. Cancer Lett. 420,
228–235 (2018).
10. Wiertz EJ, Mukherjee S, Ploegh HL. Viruses use stealth technology to escape from the host immune system. Mol. Med. Today 3(3),
116–123 (1997).
11. Hilleman MR. Strategies and mechanisms for host and pathogen survival in acute and persistent viral infections. Proc. Natl Acad. Sci.
USA 101(Suppl. 2), 14560–14566 (2004).
12. Honegger A, Schilling D, Bastian S et al. Dependence of intracellular and exosomal microRNAs on viral E6/E7 oncogene expression in
HPV-positive tumor cells. PLoS Pathog. 11(3), e1004712 (2015).
13. Yogev O, Henderson S, Hayes MJ et al. Herpesviruses shape tumour microenvironment through exosomal transfer of viral microRNAs.
PLoS Pathog. 13(8), e1006524 (2017).
14. Crenshaw BJ, Sims B, Matthews QL. Biological function of exosomes as diagnostic markers and therapeutic delivery vehicles in
carcinogenesis and infectious diseases. In: Muhammad Akhyar Farrukh (Ed). Nanomedicines. IntechOpen, London, UK (2018).
15. Ya´n˜ez-Mo´ M, Siljander PR-M, Andreu Z et al. Biological properties of extracellular vesicles and their physiological functions. J. Extracell.
Vesicles 4(1), 27066 (2015).
16. Raposo G, Stoorvogel W. Extracellular vesicles: exosomes, microvesicles, and friends. J. Cell Biol. 200(4), 373–383 (2013).
17. Fe´vrier B, Raposo G. Exosomes: endosomal-derived vesicles shipping extracellular messages. Curr. Opin. Cell Biol. 16(4), 415–421
(2004).
18. Colombo M, Moita C, Van Niel G et al. Analysis of ESCRT functions in exosome biogenesis, composition and secretion highlights the
heterogeneity of extracellular vesicles. J. Cell Sci. 126(24), 5553–5565 (2013).
19. Deng Y, Wang CC, Choy KW et al. Therapeutic potentials of gene silencing by RNA interference: principles, challenges, and new
strategies. Gene 538(2), 217–227 (2014).
20. Kubowicz P, Zelaszczyk D, Pekala E. RNAi in clinical studies. Curr. Med. Chem. 20(14), 1801–1816 (2013).
21. Hayes J, Peruzzi PP, Lawler S. MicroRNAs in cancer: biomarkers, functions and therapy. Trends Mol. Med. 20(8), 460–469 (2014).
22. Huntzinger E, Izaurralde E. Gene silencing by microRNAs: contributions of translational repression and mRNA decay. Nat. Rev. Genet.
12(2), 99 (2011).
23. Camilleri ET, Gustafson MP, Dudakovic A et al. Identification and validation of multiple cell surface markers of clinical-grade
adipose-derived mesenchymal stromal cells as novel release criteria for good manufacturing practice-compliant production. Stem Cell Res.
Ther. 7(1), 107 (2016).
24. Ghaneialvar H, Soltani L, Rahmani HR, Lotfi AS, Soleimani M. Characterization and classification of mesenchymal stem cells in several
species using surface markers for cell therapy purposes. Indian J. Clin. Biochem. 33(1), 46–52 (2018).
25. Bashiri H, Amiri F, Hosseini A et al. Dual preconditioning: a novel strategy to withstand mesenchymal stem cells against harsh
microenvironments. Adv. Pharm. Bull. 8(3), 465 (2018).
26. Hosseini S, Taghiyar L, Safari F, Eslaminejad MB. Regenerative medicine applications of mesenchymal stem cells. In: Cell Biology and
Translational Medicine, Volume 2. Springer, 115–141 (2018).
27. Rohban R, Pieber TR. Mesenchymal stem and progenitor cells in regeneration: tissue specificity and regenerative potential. Stem Cell.
Int. 2017, 5173732 (2017).
28. Rodini CO, Da Silva PBG, Assoni AF, Carvalho VM, Okamoto OK. Mesenchymal stem cells enhance tumorigenic properties of human
glioblastoma through independent cell-cell communication mechanisms. Oncotarget 9(37), 24766 (2018).
29. Cheng X, Zhang G, Zhang L et al. Mesenchymal stem cells deliver exogenous miR-21 via exosomes to inhibit nucleus pulposus cell
apoptosis and reduce intervertebral disc degeneration. J. Cell. Mol. Med. 22(1), 261–276 (2018).
30. Roushandeh AM, Bahadori M, Roudkenar MH. Mesenchymal stem cell-based therapy as a new horizon for kidney injuries. Arch. Med.
Res. 48(2), 133–146 (2017).
31. Amiri F, Jahanian-Najafabadi A, Roudkenar MH. In vitro augmentation of mesenchymal stem cells viability in stressful
microenvironments. Cell Stress Chaperones 20(2), 237–251 (2015).
32. Zhaleh F, Amiri F, Mohammadzadeh-Vardin M et al. Nuclear factor erythroid-2 related factor 2 overexpressed mesenchymal stem cells
transplantation, improves renal function, decreases injuries markers and increases repair markers in glycerol-induced Acute kidney injury
rats. Iran. J. Basic Med. Sci. 19(3), 323 (2016).
366 Epigenomics (2020) 12(4) future science group
Exosomal miRNAs in viral infections Review
33. Zhou J, Tan X, Tan Y, Li Q, Ma J, Wang G. Mesenchymal stem cell derived exosomes in cancer progression, metastasis and drug
delivery: a comprehensive review. J. Cancer 9(17), 3129 (2018).
34. Qiu G, Zheng G, Ge M et al. Mesenchymal stem cell-derived extracellular vesicles affect disease outcomes via transfer of microRNAs.
Stem Cell Res. Ther. 9(1), 320 (2018).
35. Yeo RWY, Lai RC, Zhang B et al. Mesenchymal stem cell: an efficient mass producer of exosomes for drug delivery. Adv. Drug Delivery
Rev. 65(3), 336–341 (2013).
36. Nakamura Y, Miyaki S, Ishitobi H et al. Mesenchymal-stem-cell-derived exosomes accelerate skeletal muscle regeneration. FEBS Lett.
589(11), 1257–1265 (2015).
37. Bai L, Shao H, Wang H et al. Effects of mesenchymal stem cell-derived exosomes on experimental autoimmune uveitis. Sci. Rep. 7(1),
4323 (2017).
38. Sun L, Li D, Song K et al. Exosomes derived from human umbilical cord mesenchymal stem cells protect against cisplatin-induced
ovarian granulosa cell stress and apoptosis in vitro. Sci. Rep. 7(1), 2552 (2017).
39. Pachler K, Ketterl N, Desgeorges A et al. An in vitro potency assay for monitoring the immunomodulatory potential of stromal
cell-derived extracellular vesicles. Int. J. Mol. Sci. 18(7), 1413 (2017).
40. Chan JA, Krichevsky AM, Kosik KS. MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res. 65(14),
6029–6033 (2005).
41. Reza-Zaldivar EE, Hernandez-Sapie´ns MA, Minjarez B, Gutierrez-Mercado YK, Marquez-Aguirre AL, Canales-Aguirre AA. Potential
effects of MSC-derived exosomes in neuroplasticity in Alzheimer’s disease. Front. Cell. Neurosci. 12(317) (2018).
42. Xin H, Wang F, Li Y et al. Secondary release of exosomes from astrocytes contributes to the increase in neural plasticity and
improvement of functional recovery after stroke in rats treated with exosomes harvested from microRNA 133b-overexpressing
multipotent mesenchymal stromal cells. Cell Transplant. 26(2), 243–257 (2017).
43. Caruso S, Poon IK. Apoptotic cell-derived extracellular vesicles: more than just debris. Front. Immunol. 9, 1486 (2018).
44. Xin H, Li Y, Cui Y, Yang JJ, Zhang ZG, Chopp M. Systemic administration of exosomes released from mesenchymal stromal cells
promote functional recovery and neurovascular plasticity after stroke in rats. J. Cereb. Blood Flow Metab. 33(11), 1711–1715 (2013).
45. Janas MM, Khaled M, Schubert S et al. Feed-forward microprocessing and splicing activities at a microRNA–containing intron. PLoS
Genet. 7(10), e1002330 (2011).
46. Achkar NP, Cambiagno DA, Manavella PA. miRNA biogenesis: a dynamic pathway. Trends Plant Sci. 21(12), 1034–1044 (2016).
47. Siomi H, Siomi MC. Posttranscriptional regulation of microRNA biogenesis in animals. Mol. Cell 38(3), 323–332 (2010).
48. Meijer HA, Smith EM, Bushell M. Regulation of miRNA strand selection: follow the leader? Biochem. Soc. Trans. 42(4), 1135–1140
(2014).
49. Kim VN, Han J, Siomi MC. Biogenesis of small RNAs in animals. Nat. Rev. Mol. Cell Biol. 10(2), 126 (2009).
50. Okada C, Yamashita E, Lee SJ et al. A high-resolution structure of the pre-microRNA nuclear export machinery. Science 326(5957),
1275–1279 (2009).
51. He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat. Rev. Genet. 5(7), 522 (2004).
52. Bang C, Batkai S, Dangwal S et al. Cardiac fibroblast-derived microRNA passenger strand-enriched exosomes mediate cardiomyocyte
hypertrophy. J. Clin. Invest. 124(5), 2136–2146 (2014).
53. Koppers-Lalic D, Hackenberg M, Bijnsdorp IV et al. Nontemplated nucleotide additions distinguish the small RNA composition in cells
from exosomes. Cell Rep. 8(6), 1649–1658 (2014).
54. Janas T, Janas MM, Sapon K, Janas T. Mechanisms of RNA loading into exosomes. FEBS Lett. 589(13), 1391–1398 (2015).
55. Janas T, Janas T. The selection of aptamers specific for membrane molecular targets. Cell Mol. Biol. Lett. 16(1), 25–39 (2011).
56. Janas T, Janas T, Yarus M. Human tRNA(Sec) associates with HeLa membranes, cell lipid liposomes, and synthetic lipid bilayers. RNA
18(12), 2260–2268 (2012).
57. Janas T, Yarus M. Visualization of membrane RNAs. RNA 9(11), 1353–1361 (2003).
58. Vlassov A, Khvorova A, Yarus M. Binding and disruption of phospholipid bilayers by supramolecular RNA complexes. Proc. Natl Acad.
Sci. USA 98(14), 7706–7711 (2001).
59. Khvorova A, Kwak YG, Tamkun M, Majerfeld I, Yarus M. RNAs that bind and change the permeability of phospholipid membranes.
Proc. Natl Acad. Sci. USA 96(19), 10649–10654 (1999).
• Raft-like areas on the cytoplasmic surface of the multivesicular body (MVB) membrane are the regions for loading different
RNAs into exosomes.
60. Janas T, Janas T, Yarus M. A membrane transporter for tryptophan composed of RNA. RNA 10(10), 1541–1549 (2004).
61. Tani M, Hannun YA. Neutral sphingomyelinase 2 is palmitoylated on multiple cysteine residues. Role of palmitoylation in subcellular
localization. J. Biol. Chem. 282(13), 10047–10056 (2007).
future science group www.futuremedicine.com 367
Review Nahand, Tehran, Moghoofei et al.
62. Wu BX, Clarke CJ, Matmati N, Montefusco D, Bartke N, Hannun YA. Identification of novel anionic phospholipid binding domains in
neutral sphingomyelinase 2 with selective binding preference. J. Biol. Chem. 286(25), 22362–22371 (2011).
63. Rappa G, Mercapide J, Anzanello F, Pope RM, Lorico A. Biochemical and biological characterization of exosomes containing
prominin-1/CD133. Mol. Cancer 12(1), 62 (2013).
64. Record M, Carayon K, Poirot M, Silvente-Poirot S. Exosomes as new vesicular lipid transporters involved in cell–cell communication
and various pathophysiologies. Biochim. Biophys. Acta 1841(1), 108–120 (2014).
65. Kajimoto T, Okada T, Miya S, Zhang L, Nakamura S-I. Ongoing activation of sphingosine 1-phosphate receptors mediates maturation
of exosomal multivesicular endosomes. Nat. Commun. 4, 2712 (2013).
66. Gulbins E, Kolesnick R. Raft ceramide in molecular medicine. Oncogene 22(45), 7070 (2003).
67. Chiantia S, Kahya N, Ries J, Schwille P. Effects of ceramide on liquid-ordered domains investigated by simultaneous AFM and FCS.
Biophys. J. 90(12), 4500–4508 (2006).
68. And I, Johnston LJ. Ceramide promotes restructuring of model raft membranes. Langmuir 22(26), 11284–11289 (2006).
69. Nurminen TA, Holopainen JM, Zhao H, Kinnunen PK. Observation of topical catalysis by sphingomyelinase coupled to microspheres.
J. Am. Chem. Soc. 124(41), 12129–12134 (2002).
70. Trajkovic K, Hsu C, Chiantia S et al. Ceramide triggers budding of exosome vesicles into multivesicular endosomes. Science 319(5867),
1244–1247 (2008).
• Lipid-mediated inward budding of the raft-like area of the MVB membrane is a mechanism to load different RNAs into
exosomes.
71. Kosaka N, Iguchi H, Yoshioka Y, Takeshita F, Matsuki Y, Ochiya T. Secretory mechanisms and intercellular transfer of microRNAs in
living cells. J. Biol. Chem. 285(23), 17442–17452 (2010).
72. Llorente A, Skotland T, Sylva¨nne T et al. Molecular lipidomics of exosomes released by PC-3 prostate cancer cells. Biochim. Biophys. Acta
1831(7), 1302–1309 (2013).
73. Balestrieri B, Hsu VW, Gilbert H et al. Group V secretory phospholipase A2 translocates to the phagosome after zymosan stimulation of
mouse peritoneal macrophages and regulates phagocytosis. J. Biol. Chem. 281(10), 6691–6698 (2006).
74. Prinetti A, Chigorno V, Prioni S et al. Changes in the lipid turnover, composition, and organization, as sphingolipid-enriched membrane
domains, in rat cerebellar granule cells developing in vitro. J. Biol. Chem. 276(24), 21136–21145 (2001).
75. Sonnino S, Prinetti A, Mauri L, Chigorno V, Tettamanti G. Dynamic and structural properties of sphingolipids as driving forces for the
formation of membrane domains. Chem. Rev. 106(6), 2111–2125 (2006).
76. De Gassart A, Ge´minard C, Fe´vrier B, Raposo G, Vidal M. Lipid raft-associated protein sorting in exosomes. Blood 102(13), 4336–4344
(2003).
77. Gibbings DJ, Ciaudo C, Erhardt M, Voinnet O. Multivesicular bodies associate with components of miRNA effector complexes and
modulate miRNA activity. Nat. Cell Biol. 11(9), 1143 (2009).
• RNA binding to the raft-like areas of the MVB membrane is a mechanism for loading different RNAs into exosomes.
78. Hullin-Matsuda F, Taguchi T, Greimel P, Kobayashi T. Lipid compartmentalization in the endosome system. Presented at: Seminars in
Cell & Developmental Biology 31, 48–56 (2014).
79. Janas T, Janas T, Yarus M. Specific RNA binding to ordered phospholipid bilayers. Nucleic Acids Res. 34(7), 2128–2136 (2006).
80. Carayon K, Chaoui K, Ronzier E et al. Proteolipidic composition of exosomes changes during reticulocyte maturation. J. Biol. Chem.
286(39), 34426–34439 (2011).
81. Batagov AO, Kurochkin IV. Exosomes secreted by human cells transport largely mRNA fragments that are enriched in the
3’-untranslated regions. Biol. Direct 8, 12 (2013).
82. Kajimoto T, Okada T, Miya S, Zhang L, Nakamura S. Ongoing activation of sphingosine 1-phosphate receptors mediates maturation of
exosomal multivesicular endosomes. Nat. Commun. 4, 2712 (2013).
83. Batagov AO, Kuznetsov VA, Kurochkin IV. Identification of nucleotide patterns enriched in secreted RNAs as putative cis-acting
elements targeting them to exosome nano-vesicles. BMC Genom. 12(Suppl. 3), S18 (2011).
84. Villarroya-Beltri C, Gutierrez-Vazquez C, Sanchez-Cabo F et al. Sumoylated hnRNPA2B1 controls the sorting of miRNAs into
exosomes through binding to specific motifs. Nat. Commun. 4, 2980 (2013).
85. Janas T, Janas T, Yarus M. Specific RNA binding to ordered phospholipid bilayers. Nucleic Acids Res. 34(7), 2128–2136 (2006).
86. Janas MM, Wang B, Harris AS et al. Alternative RISC assembly: binding and repression of microRNA-mRNA duplexes by human Ago
proteins. RNA 18(11), 2041–2055 (2012).
87. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 136(2), 215–233 (2009).
•• Shows that a variety of exosomal miRNAs are involved in viral infections.
88. Guarnieri DJ, Dileone RJ. MicroRNAs: a new class of gene regulators. Ann. Med. 40(3), 197–208 (2008).
89. Stoorvogel W. Functional transfer of microRNA by exosomes. Blood 119(3), 646–648 (2012).
368 Epigenomics (2020) 12(4) future science group
Exosomal miRNAs in viral infections Review
90. Boon RA, Vickers KC. Intercellular transport of microRNAs. Arterioscler. Thromb. Vasc. Biol. 33(2), 186–192 (2013).
91. Maemura T, Fukuyama S, Sugita Y et al. Lung-derived exosomal miR-483-3p regulates the innate immune response to influenza virus
infection. J. Infect. Dis. 217(9), 1372–1382 (2018).
92. Kim JH, Lee CH, Lee S-W. Exosomal transmission of microRNA from HCV replicating cells stimulates transdifferentiation in hepatic
stellate cells. Mol. Ther. Nucleic Acids 14, 483–497 (2019).
93. Chiantore MV, Mangino G, Iuliano M et al. Human papillomavirus E6 and E7 oncoproteins affect the expression of cancer-related
microRNAs: additional evidence in HPV-induced tumorigenesis. J. Cancer Res. Clin. Oncol. 142(8), 1751–1763 (2016).
94. Yoon C, Kim J, Park G et al. Delivery of miR-155 to retinal pigment epithelial cells mediated by Burkitt’s lymphoma exosomes. Tumor
Biol. 37(1), 313–321 (2016).
95. Gallo A, Vella S, Miele M et al. Global profiling of viral and cellular non-coding RNAs in Epstein–Barr virus-induced lymphoblastoid
cell lines and released exosome cargos. Cancer Lett. 388, 334–343 (2017).
96. Roth W, Huang M, Addae Konadu K, Powell M, Bond V. Micro RNA in exosomes from HIV-infected macrophages. Int. J. Environ.
Res. Public Health 13(1), 32 (2016).
97. Fu Y, Zhang L, Zhang F et al. 293tExosome-mediated miR-146a transfer suppresses type I interferon response and facilitates EV71
infection. PLoS Pathog. 13(9), e1006611 (2017).
98. Han Z, Liu X, Chen X et al. miR-H28 and miR-H29 expressed late in productive infection are exported and restrict HSV-1 replication
and spread in recipient cells. Proc. Natl Acad. Sci. USA 113(7), E894–E901 (2016).
99. Hoshina S, Sekizuka T, Kataoka M et al. Profile of exosomal and intracellular microRNA in gamma-herpesvirus-infected lymphoma cell
lines. PLoS ONE 11(9), e0162574 (2016).
100. Chugh PE, Sin S-H, Ozgur S et al. Systemically circulating viral and tumor-derived microRNAs in KSHV-associated malignancies. PLoS
Pathog. 9(7), e1003484 (2013).
101. Gourzones C, Gelin A, Bombik I et al. Extra-cellular release and blood diffusion of BART viral micro-RNAs produced by EBV-infected
nasopharyngeal carcinoma cells. Virol. J. 7(1), 271 (2010).
•• Shows that exosomal miRNAs play a role in infections with DNA viruses.
102. Choi H, Lee H, Kim SR, Gho YS, Lee SK. Epstein-Barr virus-encoded microRNA BART15-3p promotes cell apoptosis partially by
targeting BRUCE. J. Virol. 87(14), 8135–8144 (2013).
103. Choi H, Lee SK. TAX1BP1 downregulation by EBV-miR-BART15-3p enhances chemosensitivity of gastric cancer cells to 5-FU. Arch.
Virol. 162(2), 369–377 (2017).
104. Pegtel DM, Cosmopoulos K, Thorley-Lawson DA et al. Functional delivery of viral miRNAs via exosomes. Proc. Natl Acad. Sci. USA
107(14), 6328–6333 (2010).
105. Nuovo GJ, Garofalo M, Valeri N et al. Reovirus-associated reduction of microRNA-let-7d is related to the increased apoptotic death of
cancer cells in clinical samples. Mod. Pathol. 25(10), 1333 (2012).
106. Volinia S, Galasso M, Sana ME et al. Breast cancer signatures for invasiveness and prognosis defined by deep sequencing of microRNA.
Proc. Natl Acad. Sci. USA 109(8), 3024–3029 (2012).
107. Di Leva G, Garofalo M, Croce CM. MicroRNAs in cancer. Ann. Rev. Pathol. 9, 287–314 (2014).
108. Harden ME, Munger K. Human papillomavirus 16 E6 and E7 oncoprotein expression alters microRNA expression in extracellular
vesicles. Virology 508, 63–69 (2017).
109. Pakfetrat M, Yaghobi R, Salmanpoor Z, Roozbeh J, Torabinezhad S, Kadkhodaei S. Frequency of polyomavirus BK infection in kidney
transplant patients suspected to nephropathy. Int. J. Organ Transplant. Med. 6(2), 77–84 (2015).
110. Hirsch HH, Brennan DC, Drachenberg CB et al. Polyomavirus-associated nephropathy in renal transplantation: interdisciplinary
analyses and recommendations. Transplantation 79(10), 1277–1286 (2005).
111. Tian YC, Li YJ, Chen HC et al. Polyomavirus BK-encoded microRNA suppresses autoregulation of viral replication. Biochem. Biophys.
Res. Commun. 447(3), 543–549 (2014).
112. Kim MH, Lee YH, Seo JW et al. Urinary exosomal viral microRNA as a marker of BK virus nephropathy in kidney transplant recipients.
12(12), e0190068 (2017).
113. Knowles WA, Pipkin P, Andrews N et al. Population-based study of antibody to the human polyomaviruses BKV and JCV and the
simian polyomavirus SV40. J. Med. Virol. 71(1), 115–123 (2003).
114. Egli A, Infanti L, Dumoulin A et al. Prevalence of polyomavirus BK and JC infection and replication in 400 healthy blood donors. J.
Infect. Dis. 199(6), 837–846 (2009).
115. Polo C, Perez J, Mielnichuck A, Fedele C, Niubo J, Tenorio A. Prevalence and patterns of polyomavirus urinary excretion in
immunocompetent adults and children. Clin. Microbiol. Infect. 10(7), 640–644 (2004).
116. Bayer A, Delorme-Axford E, Sleigher C et al. Human trophoblasts confer resistance to viruses implicated in perinatal infection. Am. J.
Obstet. Gynecol. 212(1), 71.e71–71.e78 (2015).
future science group www.futuremedicine.com 369
Review Nahand, Tehran, Moghoofei et al.
117. Delorme-Axford E, Donker RB, Mouillet J-F et al. Human placental trophoblasts confer viral resistance to recipient cells. Proc. Natl
Acad. Sci. USA 110(29), 12048–12053 (2013).
118. Payne L, Venugopal K. Neoplastic diseases: Marek’s disease, avian leukosis and reticuloendotheliosis. Rev. Sci. Tech. 19(2), 544–560
(2000).
119. Powell P, Payne L, Frazier JA, Rennie M. T lymphoblastoid cell lines from Marek’s disease lymphomas. Nature 251(5470), 79–80 (1974).
120. Neerukonda SN, Tavlarides-Hontz P, Mccarthy F, Pendarvis K, Parcells MS. Comparison of the transcriptomes and proteomes of serum
exosomes from Marek’s disease virus-vaccinated and protected and lymphoma-bearing chickens. Genes 10(2), 116 (2019).
•• Shows that exosomal miRNAs play a role in infections with RNA viruses.
121. Bernard MA, Zhao H, Yue SC, Anandaiah A, Koziel H, Tachado SD. Novel HIV-1 miRNAs stimulate TNFα release in human
macrophages via TLR8 signaling pathway. PLoS ONE 9(9), e106006 (2014).
122. Hu G, Yao H, Chaudhuri A et al. Exosome-mediated shuttling of microRNA-29 regulates HIV Tat and morphine-mediated neuronal
dysfunction. Cell Death Dis. 3(8), e381 (2012).
123. Chahar H, Bao X, Casola A. Exosomes and their role in the life cycle and pathogenesis of RNA viruses. Viruses 7(6), 3204–3225 (2015).
124. Shrivastava S, Steele R, Ray R, Ray RB. MicroRNAs: role in hepatitis C virus pathogenesis. Genes Dis. 2(1), 35–45 (2015).
125. Kim JH, Lee CH, Lee S-W. Hepatitis C virus infection stimulates transforming growth factor-β1 expression through up-regulating
miR-192. J. Microbiol. 54(7), 520–526 (2016).
126. Xiong L, Zhen S, Yu Q, Gong Z. HCV-E2 inhibits hepatocellular carcinoma metastasis by stimulating mast cells to secrete exosomal
shuttle microRNAs. Oncol. Lett. 14(2), 2141–2146 (2017).
127. Wang Y, Yi J, Chen X, Zhang Y, Xu M, Yang Z. The regulation of cancer cell migration by lung cancer cell-derived exosomes through
TGF-β and IL-10. Oncol. Lett. 11(2), 1527–1530 (2016).
128. Cheung KL, Jarrett R, Subramaniam S et al. Psoriatic T cells recognize neolipid antigens generated by mast cell phospholipase delivered
by exosomes and presented by CD1a. J. Exp. Med. 213(11), 2399–2412 (2016).
129. Jia Z, Liu Y, Gao Q et al. miR-490-3p inhibits the growth and invasiveness in triple-negative breast cancer by repressing the expression of
TNKS2. Gene 593(1), 41–47 (2016).
130. Xu X, Chen R, Li Z et al. MicroRNA-490-3p inhibits colorectal cancer metastasis by targeting TGFβR1. BMC Cancer 15(1), 1023
(2015).
131. Chen S, Chen X, Xiu Y-L, Sun K-X, Zhao Y. MicroRNA-490-3P targets CDK1 and inhibits ovarian epithelial carcinoma tumorigenesis
and progression. Cancer Lett. 362(1), 122–130 (2015).
132. Zhang L-Y, Liu M, Li X, Tang H. miR-490-3p modulates cell growth and epithelial to mesenchymal transition of hepatocellular
carcinoma cells by targeting endoplasmic reticulum-Golgi intermediate compartment protein 3 (ERGIC3). J. Biol. Chem. 288(6),
4035–4047 (2013).
133. Xu J, Zhang X, Wang H et al. HCRP1 downregulation promotes hepatocellular carcinoma cell migration and invasion through the
induction of EGFR activation and epithelial-mesenchymal transition. Biomed. Pharmacother. 88, 421–429 (2017).
134. Cao C, Lu S, Sowa A et al. Priming with EGFR tyrosine kinase inhibitor and EGF sensitizes ovarian cancer cells to respond to
chemotherapeutical drugs. Cancer Lett. 266(2), 249–262 (2008).
135. Lin F-C, Young HA. Interferons: success in anti-viral immunotherapy. Cytokine Growth Factor Rev. 25(4), 369–376 (2014).
136. Ho B-C, Yu I-S, Lu L-F et al. Inhibition of miR-146a prevents enterovirus-induced death by restoring the production of type I
interferon. Nat. Commun. 5, 3344 (2014).
137. Valadi H, Ekstro¨m K, Bossios A, Sjo¨strand M, Lee JJ, Lo¨tvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel
mechanism of genetic exchange between cells. Nat. Cell Biol. 9(6), 654 (2007).
138. Liu C-C, Guo M-S, Lin FH-Y et al. Purification and characterization of enterovirus 71 viral particles produced from vero cells grown in a
serum-free microcarrier bioreactor system. PLoS ONE 6(5), e20005 (2011).
139. Mao L, Wu J, Shen L, Yang J, Chen J, Xu H. Enterovirus 71 transmission by exosomes establishes a productive infection in human
neuroblastoma cells. Virus Genes 52(2), 189–194 (2016).
140. Rekker K, Saare M, Roost AM et al. Comparison of serum exosome isolation methods for microRNA profiling. Clin. Biochem. 47(1-2),
135–138 (2014).
141. Gyo¨rgy B, Mo´dos K, Pa´llinger E´ et al. Detection and isolation of cell-derived microparticles are compromised by protein complexes
resulting from shared biophysical parameters. Blood 117(4), e39–e48 (2011).
142. Narayanan A, Iordanskiy S, Das R et al. Exosomes derived from HIV-1-infected cells contain trans-activation response element RNA. J.
Biol. Chem. 288(27), 20014–20033 (2013).
•• Shows that exosomes play a role in HIV viral infection.
143. Esser MT, Graham DR, Coren LV et al. Differential incorporation of CD45, CD80 (B7-1), CD86 (B7-2), and major histocompatibility
complex class I and II molecules into human immunodeficiency virus type 1 virions and microvesicles: implications for viral pathogenesis
and immune regulation. J. Virol. 75(13), 6173–6182 (2001).
370 Epigenomics (2020) 12(4) future science group
